136.30USD+3.49%Mkt Cap: 169.23B $P/E: 18.541d ago
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, D…
Industry Peers
Drug Manufacturers - General$1.04TUSDP/E 41.6
$601.73BUSDP/E 29.0
$449.42BUSDP/E 124.1
$305.83BUSDP/E 21.0
$315.22BUSDP/E 36.0
$272.16BUSDP/E 21.8
$268.42BUSDP/E 21.8
$243.51BUSDP/E 25.4
$216.37BUSDP/E 12.3
$212.87BUSDP/E 25.1
$200.54BUSDP/E 25.9
$143.28BUSDP/E 19.2
$123.57BUSDP/E 16.9
$100.10BUSDP/E 19.4
$85.16BUSDP/E 13.8
$50.96BUSD
$30.84BUSDP/E 22.4
MRV
Marvell Technology, Inc.$20.08BUSDP/E 7.4
$11.37BUSDP/E 22.7
$10.53BUSDP/E 18.3
$10.47BUSDP/E 18.2
$6.76BUSDP/E 15.0
$3.54BUSDP/E 14.5
$2.97BUSDP/E 18.1
$61.82MUSD
$39.24MUSD
ELXR
Elixxer Ltd.$9.51MUSD
FLXN
Horizon Flexible Income ETF—P/E 27.0
CELG-RI
Bristol-Myers Squibb Company Ce—
ROSE
DocMorris AG—
FR0000140022
SANOFITP29OCT49—
Indicators:|
Key Statistics
Company
Market Cap169.23B $
Enterprise Value175.79B $
Revenue (TTM)29.74B $
Gross Profit23.21B $
Net Income (TTM)8.51B $
Revenue/Share23.92 USD
Last Price136.30 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees17.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS3755581036
Valuation
P/E (Trailing)18.54
P/E (Forward)14.03
PEG2.14
EV/EBITDA11.93
EV/Revenue5.91
P/S5.69
P/B7.20
EPS (TTM)7.35
EPS (Forward)9.71
52W Range
107.7558% of range157.29
52W High157.29 USD
52W Low107.75 USD
Profitability
Gross Margin78.83%
Oper. Margin39.28%
EBITDA Margin49.56%
Profit Margin28.90%
ROE37.49%
ROA14.42%
Growth
Revenue Growth4.40%
Earnings Growth54.80%
Cash Flow & Leverage
Operating CF10.02B $
CapEx (TTM)563.00M $
FCF Margin26.68%
FCF Yield4.69%
Net Debt12.36B $
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity1.10
Current Ratio1.97
Quick Ratio1.54
Book Value/Sh18.93 USD
Cash/Share7.907 USD
Dividends
Fwd Div Rate—
Trail. Div Rate3.190 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateJun 29, 2026
Splits
Last Split2:1
Split DateJan 28, 2013
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)158.30 USD
Upside (mean)+16.1%
Target Range120.00 USD – 180.00 USD
$120.00+16.1% to mean$180.00
# Analysts27
Ownership
Shares Out.1.24B
Float1.24B
Insiders0.12%
Institutions92.18%
Short Interest
Short Ratio2.7d
Short % Float2.05%
Short % Out.2.05%
Shares Short25.48M
Short (prev mo.)25.73M
Technical
SMA 50129.89 (+4.9%)
SMA 200130.71 (+4.3%)
Beta0.34
S&P 52W Chg20.25%
Avg Vol (30d)7.91M
Avg Vol (10d)6.97M
Technical Indicators
RSI (14)60.7
MACD1.2361
MACD Signal0.3846
MACD Hist.+0.8515
BB Upper136.63 USD
BB Middle128.66 USD
BB Lower120.69 USD
BB Width12.38%
ATR (14)3.847 USD
Vol Ratio (20d)0.96x